Key Takeaways
- The US FDA has approved AbbVie’s new drug tavapadon, branded as Juvmo, for treating Parkinson’s disease.
- Juvmo is a once-daily pill that mimics dopamine, a brain chemical that declines in Parkinson’s patients.
- Common side effects include nausea, dizziness, and headaches, according to clinical trials.
The US Food and Drug Administration (FDA) has given its approval to AbbVie’s new treatment for Parkinson’s disease, tavapadon, which will be marketed under the brand name Juvmo. This approval comes after AbbVie acquired the drug through its $8.7 billion purchase of Cerevel Therapeutics in 2023.
Parkinson’s disease is a chronic brain disorder that affects movement control and can lead to tremors, stiffness, and balance issues. The disease affects more than 11 million people worldwide, according to AbbVie.
Juvmo works by mimicking dopamine, a vital brain chemical that naturally declines in individuals with Parkinson’s disease. The drug was approved based on data from AbbVie’s late-stage trial programme, which demonstrated that Juvmo improved symptoms in patients.
Common side effects reported in the trials include nausea, dizziness, and headaches. These side effects are typical of many Parkinson’s disease treatments and are expected to be managed by healthcare providers.
AbbVie did not immediately comment on the drug’s launch or pricing. However, Citi analysts had previously predicted that the launch would occur in the third quarter of 2026, with uptake likely to be gradual due to ongoing Medicare coverage negotiations.
The approval of Juvmo marks a significant step forward in the treatment of Parkinson’s disease, offering a new option for patients seeking relief from the symptoms of the condition.
While the drug’s launch is expected to be gradual, it represents a promising development for those living with Parkinson’s disease. AbbVie’s acquisition of Cerevel Therapeutics underscores the company’s commitment to advancing treatments for neurological conditions.
The approval of Juvmo is based on robust clinical data, which demonstrated its efficacy in improving symptoms for patients with Parkinson’s disease. As the drug becomes available, healthcare providers will be able to offer this new treatment to their patients.
